| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
| 2. Date of Event Requiring Statement (Month/Day/Year) 04/20/2021 | 3. Issuer Name and Ticker or Trading Symbol Akoya Biosciences, Inc. [ AKYA ] | |||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
| 5. If Amendment, Date of Original Filed (Month/Day/Year) | ||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| No securities are beneficially owned. | 0 | D | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Employee Stock Option (Right to Buy) | (1) | 11/09/2027 | Common Stock | 353,129 | 0.3 | D | |
| Employee Stock Option (Right to Buy) | (2) | 11/09/2027 | Common Stock | 117,709 | 0.3 | D | |
| Employee Stock Option (Right to Buy) | (3) | 05/02/2029 | Common Stock | 248,318 | 0.44 | D | |
| Employee Stock Option (Right to Buy) | (2) | 05/02/2029 | Common Stock | 82,772 | 0.44 | D | |
| Employee Stock Option (Right to Buy) | (4) | 03/24/2031 | Common Stock | 214,592 | 16.12 | D | |
| Explanation of Responses: |
| 1. The option vested as to one-fourth of the shares on July 14, 2018 with the remaining shares vesting in 36 equal monthly installments beginning on July 14, 2018, until fully vested, subject to reporting person's continuous employment. |
| 2. Such performance-based option shares were issued in 2017 and 2019, respectively. In 2020, the options vested as performance conditions were determined to have been achieved. |
| 3. The option vested as to one-fourth (1/4) of the shares on September 26, 2019 with the remaining shares vesting in 36 equal monthly installments beginning on September 26, 2019, until fully vested, subject to reporting person's continuous employment. |
| 4. The option shall vest with respect to (1/4) of such shares on March 22, 2022 and the remaining shares shall vest in 36 equal monthly installments beginning on March 22, 2022, until fully vested, subject to reporting person's continuous employment. |
| Remarks: |
| Exhibit 24.1 Power of Attorney |
| /s/ Brian McKelligon, Joseph Driscoll, Attorney-in-Fact | 04/20/2021 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
